MEN1 and acute lymphoblastic leukemia: Hence, simultaneously targeting menin and DOT1L may represent a therapeutic strategy worth exploring in KMT2A-rearranged ALL patients, especially since improved inhibitors with more favorable pharmacokinetic profiles are being developed [41,42,43].